iReporter
 
Pin on Pinterest

Level III NICU Designation Awarded to Medical City Plano

Medical City Plano continues to care for babies at a higher level

The neonatal intensive care unit at Medical City Plano has been officially designated as a Level III facility from the Texas Department of Health Services.

A Level III NICU designation is the second to highest level of neonatal care and reflects Medical City Plano’s ability to provide optimal care for critically ill newborns. State law requires all NICUs to undergo rigorous evaluation and verification to ensure they meet stringent clinical care guidelines set by the American Academy of Pediatrics. Medical City Plano has 42 beds available in its Level III NICU.  

“As this community’s first hospital, Medical City Plano has been the healthcare leader for generations,” says Charles Gressle, CEO of Medical City Plano. “Maintaining this advanced Level III NICU designation, with a family-centered philosophy, reinforces our commitment to providing all mothers and babies that come through our doors with excellent care.”

Medical City Plano’s Level III NICU provides comprehensive care to premature, critically ill or medically fragile infants. A multidisciplinary team of dedicated neonatologists, pediatric surgeons, subspecialists and nurses certified in neonatal care provide sophisticated and focused diagnostic, therapeutic and surgical care for infants delivered as early as 23 weeks.

About Medical City Plano:

Medical City Plano is a full-service, 513 bed, acute-care facility with more than 2,000 employees and 1,400 physicians representing more than 70 specialties and subspecialties. Accredited by The Joint Commission, Medical City Plano is a Level I Trauma Center with a Burn and Reconstructive Center, a Comprehensive (Level I) Stroke Center, a Level III NICU and Collin County’s first Chest Pain Accredited hospital. Magnet designated for nursing excellence, Medical City Plano is part of Medical City Healthcare.

For more information: MedicalCityPlano.com or follow us on Facebook and Twitter.